ANKK1 Genotype

If quitting smoking has been harder for you than it looks for everyone else, part of the explanation may be written on chromosome 11. A common inherited variant near the gene for your brain's main dopamine receptor tracks with lower receptor availability in the reward centers, and in the largest pooled analysis, with lower odds of a quit attempt sticking. A genetic test tells you whether you carry it.

This is research genetics, not a diagnosis. No clinical cutpoints exist, no treatment guideline turns on the result, and carrying a risk version does not mean you will develop anything. What you get is one fixed piece of context about your own dopamine biology, and you only have to test it once.

What This Gene Does

ANKK1 (ankyrin repeat and kinase domain containing 1) codes for a kinase. A kinase is an enzyme that changes other proteins by tagging them. Cell and animal studies suggest this gene helps neural cells mature and helps shape dopamine pathways during development.

The gene is part of a tight cluster on chromosome 11 with three neighbors, one of which is DRD2, the gene for the brain's main dopamine receptor. Studies of the cluster suggest it helps build dopamine circuits while the brain is developing. That is why variants here keep reappearing in conditions that run through reward and movement.

One variant dominates the research: Taq1A, also written rs1800497. It is a single letter change in a protein-coding stretch of the gene, and carrying the A1 version is associated with lower dopamine D2 receptor availability in the striatum. The striatum helps handle reward and motor control. Labs often write the A1 version as T and the A2 version as C, so an A1 carrier and a T carrier usually mean the same thing.

Smoking and How Hard It Is to Quit

The most-studied human question about this gene concerns quitting. A pooled analysis of 22 studies and 11,075 smokers of European ancestry found that people carrying two copies of the common A2 version quit at higher rates than those carrying one or two copies of A1, roughly 20 percent higher odds. That is an average across many studies, not a personal quit probability.

The picture is not unanimous. A separate pooled analysis of nine cessation-treatment studies covering 2,851 participants found no overall genotype effect on whether treatment worked. And a long-running study of women found the direction depended on how much a person smoked: lower odds of quitting for A1 carriers who smoked moderately or heavily, higher odds among light smokers. Treat the genotype as one piece of context, not a prediction.

Dependence itself also tracks with the region. In African American families recruited through smoking probands, variation across this gene was associated with nicotine dependence, and one change (rs2734849) altered how the gene's own control switch behaves. In a separate study of 150 smokers and 228 controls, a combination of variants spanning this gene and its receptor neighbor predicted dependence better than either variant alone.

For an A1 carrier who smokes, the useful plan is to treat quitting as a higher-friction problem from the start. Medication and structured support from day one make more sense than waiting for two failed attempts on willpower.

Alcohol and Other Substances

A large pooled analysis of alcohol dependence studies found the A1 version associated with higher risk, with a modest effect across samples. Smaller candidate-gene studies report related signals for heroin dependence in a Hungarian cohort of more than 800 people, and in 176 alcohol-dependent Spanish men, where this variant and a nearby receptor variant interacted with psychopathic-trait scores.

A later re-analysis complicated the alcohol story. Comparing reported version frequencies across decades of studies, it found that the alcohol use disorder association may come largely from comparison groups with unusually low A1 frequencies rather than from the variant doing anything functional, and that other variants in the neighboring receptor gene track the disorder more strongly.

Both findings can hold, because this variant works better as a signpost than as a cause. It travels on a chunk of chromosome inherited as a single unit, so it can flag a stretch of DNA that matters without being the piece that matters. A multiethnic Parkinson's study reached the same conclusion about the receptor gene's variants: probably not the true causal changes, but riding along with something nearby that is. Read your result as a marker for a region, not a verdict on a molecule.

Parkinson's Disease

The most specific finding here came from sequencing rather than single-variant checks. A 2025 study of people with late-onset Parkinson's disease named this gene as one of five new candidate risk genes, based on rare coding changes found more often in patients.

In the same study, carrying two or more rare variants across the candidate gene set tracked with a rougher course, including earlier age at onset, levodopa-triggered involuntary movements, and severe cognitive impairment. A Parkinson's meta-analysis found Taq1A and a BDNF variant nominally linked to time to levodopa-triggered movements, but neither survived strict correction for the number of variants tested. Rare changes in this gene's control region, the switch that sets how much protein gets made, have also appeared as Parkinson's risk factors in a Spanish cohort of 535 people.

If Parkinson's runs in your family and you carry rare changes here, the useful move is an earlier baseline neurological assessment, not treatment. Nothing in this evidence should change which medication anyone takes. It changes how closely you watch, and how early you raise movement side effects if levodopa ever enters the picture.

Antipsychotics, Restlessness, and Metabolic Drift

If you take or are about to start a dopamine-blocking medication, this is the nearest thing to an actionable association. It still rests on a single study that has not been replicated. In 234 people on antipsychotics, A1 carriers taking second-generation drugs developed akathisia about twice as often as noncarriers, roughly 24 percent versus 11 percent. Akathisia is the inner restlessness that makes sitting still feel impossible and can make medication hard to stay on. No guideline endorses using this genotype to pick an antipsychotic or to set a monitoring schedule.

The metabolic signal is weaker still. Among 104 people with schizophrenia taking olanzapine in one retrospective study, people with two T copies started with total cholesterol about 14 percent lower than people carrying two C copies, and post-treatment glucose changes tracked with genotype only faintly, a correlation around 0.24 where 1.0 would be a perfect match. The glucose link held after accounting for body weight and drug levels, but these are single-study numbers, and a link that weak does not predict what will happen to any one person.

Eating Behavior and Body Weight

Sequencing the entire coding region of this gene in 50 Mexican-Mestizo adults with obesity, half of them with binge eating disorder, alongside 100 adults with normal body weight, turned up no rare disease-causing mutations anywhere in it. What it found instead were two common variants doing different jobs: one in an early coding section associated with obesity itself, and Taq1A associated with binge eating disorder among those with obesity.

That is the cleanest argument against reading this as an obesity gene in the inherited-disease sense. It carries common variation that nudges eating behavior, not mutations that cause a condition. In 101 people who had bariatric surgery, Taq1A status tracked with eating behavior scores, not with a clear weight-loss prediction.

Tics and Other Dopamine-Linked Findings

A pooled analysis linked the Taq1A variant to Tourette syndrome susceptibility, most consistently in populations of European ancestry. Scattered single studies report other associations: a different variant in this gene (rs2734849) with psychosis in Parkinson's disease among 234 people, and this gene together with its receptor neighbor with worse oral-health quality of life in 114 men who had jaw joint disorders. Treat those as leads rather than conclusions.

Where This Result Can Mislead You

• Panel coverage: the report only describes the stretches of DNA the assay actually read. Nothing flagged means nothing was found in what was sequenced, not that the gene is clean, and changes in the gene's control region have been tied to risk here.
• Ancestry: how common each version is differs sharply between populations. The quitting data comes mostly from people of European ancestry, the functional nicotine-dependence variant was identified in African American families, and the obesity findings come from a Mexican-Mestizo cohort. A risk estimate built in one group does not transfer cleanly to another.
• Uncharacterized changes: sequencing a whole gene turns up letter changes nobody has studied yet. A report listing one of those is telling you the lab found something unusual, not that it means anything.
• Sample source: germline testing should reflect inherited DNA. A blood result after a stem-cell transplant can reflect donor DNA, and tumor-only sequencing is not a germline result.
• Consumer chip results: a direct-to-consumer report that gives you a Taq1A call is reading one probe at one position. That is far narrower than clinical sequencing across the gene, and the two are not interchangeable.

One Result, Then Decades of Use

Your genotype is the pair of gene versions you inherited. It does not change. There is no trend to follow and no reason to repeat this test. The one situation that justifies retesting is doubt about the call itself: a result from a chip-based assay, or one that clashes with what your family history would predict, is worth confirming by a second method before anyone acts on it.

What does need tracking is everything downstream. If you take an antipsychotic, get fasting glucose, HbA1c, and a lipid panel at baseline, again at 3 to 6 months, and at least annually after that. That schedule comes from standard antipsychotic monitoring practice, not from your genotype. HbA1c gives a rough three-month view of blood sugar. If Parkinson's runs strongly in your family, a baseline neurological assessment is more useful than repeating the gene test. The repeat interval is individualized; a yearly check is reasonable when family history is strong or early symptoms appear.

What to Do With a Risk Result

A risk variant on its own is context, not a reason to act. What changes the calculus is a combination: the variant plus a first-degree relative with Parkinson's disease, the variant plus early movement symptoms, the variant plus quit attempts that keep collapsing, or the variant plus a new prescription for a dopamine-blocking drug.

That leads to a few concrete moves. Order the companion labs yourself and tighten the interval if you are starting an antipsychotic. Bring the result to a neurologist before levodopa is started if Parkinson's is in your family. Bring it to whoever manages your psychiatric medications if you have ever stopped one because you could not sit still. Take it to a genetic counselor if the report lists a rare or uncharacterized change, because interpreting those is specialist work.

Then tell your siblings, parents, and children. Common variants like Taq1A run through families, and this information is only useful to them if it arrives before they start a medication or a quit attempt, not after.